精品国产一区二区桃色

Journal News

From the journals: 精品国产一区二区桃色

Nivedita Uday Hegdekar
Dec. 2, 2022

Muscling in on a signaling pathway. Probing weaknesses in the T cell surface. Improving single-cell proteomics two ways. Read about papers on these topics recently published in Molecular & Cellular Proteomics.

Muscling in on a signaling pathway

Muscle-specific receptor tyrosine kinase, or MuSK, plays an essential role in forming neuromuscular junctions. It is activated by a nerve-derived proteoglycan called agrin through low-density lipoprotein receptor–related protein 4, or LRP4. Several neuromuscular diseases are associated with the MuSK signaling pathway; in one of these, myasthenia gravis, autoantibodies target various components of that pathway. Similarly, mutations in genes that function within the pathway characterize congenital myasthenic syndromes.

Neurons stimulate the muscle cells by producing acetylcholine or similar substances at the neuromuscular junction, causing contraction of the muscle fibers.
Neurons stimulate the muscle cells by producing acetylcholine or similar substances at the neuromuscular junction, causing contraction of the muscle fibers.

Researchers use MuSK-activating antibody, an agonist antibody, or Ab, to explore the benefits of MuSK activation at the neuromuscular junction. In two recent studies, this Ab acted in an LRP4-independent manner in mouse models of amyotrophic lateral sclerosis. Both studies reported delayed denervation upon treatment with the MuSK agonist Ab, with notable differences in downstream functional outcomes. Given these observations, Hanna Budayeva and a team of researchers at Genentech used Ab to compare direct MuSK activation to coreceptor sequestration and assess how much Ab-mediated MuSK activation recapitulates the physiological agrin-mediated activation.

The team performed dose–response and time-course experiments on C2C12 myotubes and systematically compared site-specific phosphorylation downstream of MuSK activation by agrin and MuSK-activating Ab. Using mass spectrometry–based proteomics, they tested two MuSK agonists, and observed novel but similar intracellular responses at known and newly identified MuSK signaling components. Among these responses was inducible tyrosine phosphorylation of multiple Rab GTPases that was blocked by MuSK inhibition. Moreover, mutation of this site in Rab10 disrupted association with its interacting proteins.

The researchers characterized MuSK signaling in depth and identified a role for Rab GTPases in the downstream signaling of this MuSK pathway. These were recently published in the journal Molecular & Cellular Proteomics.

Probing weaknesses in the T cell surface

T cells are white blood cells that play a central role in the body’s adaptive immune response. In particular, cytotoxic T cells, or CD8+ T cells, promote tumor-cell killing and are used in cancer therapy.

Researchers know the cell surface proteome, or surfaceome, mediates T cell interactions with the external environment but do not yet fully understand how external factors affect that surfaceome. Immunosuppressive factors in the tumor microenvironment, or TME, can impair T cell function and limit the antitumor immune response by changing cell surface receptors and surface proteins.

To study surface proteome remodeling in T cells in greater detail, James Byrnes and a research team at the University of California, San Francisco, performed quantitative cell surface proteomics on primary human CD8+ T cells to determine how immunosuppressive TME factors, Tregs (regulatory T cells a specialized subpopulation of T cells that act to suppress immune response), and hypoxia affected the activated CD8+ surfaceome. Consistent with suppressed cell activation, the Tregs partly reversed activation-induced changes in CD8+ T cells. Hypoxia triggered large-scale surfaceomic remodeling consistent with a general cellular response to the metabolic demands of a low-oxygen environment. In both conditions, the researchers saw reduced expression of proteins primarily involved in nutrient transport. These changes could limit T cell nutrient uptake during activation and, subsequently, T cell proliferation.

These , recently published in the journal Molecular & Cellular Proteomics, provide insight into the plasticity of the T cell surfaceome and lay the foundation for future efforts to characterize further and therapeutically engage T cell surface proteins for better immune response.

Improving single-cell proteomics two ways

Single-cell proteomics, or scMS, uses liquid chromatography–mass spectrometry based proteomics. As this technology evolves, researchers need to better understand the proteome, both the proteins quantified per cell and the quantitative performance thereof. However, multiplexing scMS is challenging; high ion injection times and high-resolution spectra are needed to quantify the single-cell signal.

A new real-time search, or RTS, on the Orbitrap Eclipse Tribrid mass spectrometer combined with synchronous precursor selection–triple-stage mass spectrometry, or SPS-MS3, acquisition could help researchers measure samples that are multiplexed using isobaric tags. To show this, Benjamin Furtw盲ngler and a team of researchers from the University of Copenhagen, the Technical University of Denmark and other institutions compared classical MS2 acquisition to RTS-MS3 and a new RTS-MS2 acquisition method called RETICLE and found that both RTS methods outperformed classical MS2 acquisition.

The researchers recently published their in the journal Molecular & Cellular Proteomics. They found that scMS data acquisition using the tribrid design in combination with RTS can result in better scMS data sets. RTS-MS3 provided similar proteome coverage to MS2 at higher quantitative accuracy, whereas RETICLE resulted in higher proteome coverage. Thus, RETICLE could be especially useful for high-throughput applications, such as building single-cell atlases, whereas RTS-MS3 could provide the accuracy needed to model complex protein networks.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Nivedita Uday Hegdekar

Nivedita Uday Hegdekar is a recent Ph.D. graduate in biochemistry and molecular biology from the University of Maryland, Baltimore.

Get the latest from ASBMB Today

Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Omega-3 fats linked to healthy aging and improved heart metabolism
Journal News

Omega-3 fats linked to healthy aging and improved heart metabolism

Aug. 1, 2025

Scientists from the University of Iowa find that a diet high in polyunsaturated fatty acids from fish oil increases cardiac triglyceride uptake and improves insulin sensitivity. Read more about this recent JLR study.

RA patient blood reveals joint innerworkings
Journal News

RA patient blood reveals joint innerworkings

July 25, 2025

Researchers in the Netherlands use mass spectrometry to compare the proteome of plasma and synovial fluid in rheumatoid arthritis patients and find a correlation. Read more about this recent paper in Molecular & Cellular Proteomics.

Hope for a cure hangs on research
Essay

Hope for a cure hangs on research

July 17, 2025

Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson鈥檚 fight for survival and hope. Without funding, science can鈥檛 鈥渃atch up鈥 to help the patients who need it most.

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease
Feature

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease

July 15, 2025

Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal 鈥 and just getting started.

Defeating deletions and duplications
News

Defeating deletions and duplications

July 11, 2025

Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader鈥揥illi syndrome.

Using 'nature鈥檚 mistakes' as a window into Lafora disease
Feature

Using 'nature鈥檚 mistakes' as a window into Lafora disease

July 10, 2025

After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.